Pharmaceutical company Moberg Pharma AB (STO;MOB) on Monday reported net profit after tax of SEK12.3m, or diluted EPS of SEK0.71, for the third quarter of 2017, from July 2017 to September 2017.
This was in comparison with profit after tax of SEK12.8m, or diluted eps of SEK0.89, in Q3 2016.
Net revenues for the quarter were SEK108.3m, as compared with SEK104.1m in Q3 2016.
Moberg Pharma researches and produces topical treatments for skin conditions. The company is researching creams for nail fungus, dry and scaly skin, anal fissures and actinic keratosis.
(EUR1.00=SEK9.85)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government